GrippeCanadaV3, Main, Exploration, bibRecord, 000027

Cost-effectiveness of adult vaccinations: A systematic review.

Identifieur interne : 000027 ( Main/Exploration ); précédent : 000026; suivant : 000028

Cost-effectiveness of adult vaccinations: A systematic review.

Auteurs : Andrew J. Leidner [États-Unis] ; Neil Murthy [États-Unis] ; Harrell W. Chesson [États-Unis] ; Matthew Biggerstaff [États-Unis] ; Charles Stoecker [États-Unis] ; Aaron M. Harris [États-Unis] ; Anna Acosta [États-Unis] ; Kathleen Dooling [États-Unis] ; Carolyn B. Bridges [États-Unis]

Source :

Vaccine [ 1873-2518 ] ; 2019.

RBID : pubmed:30527660

Descripteurs français

KwdFr :
- Adulte, Analyse coût-bénéfice, Calendrier vaccinal, Canada, Diphtérie (), Facteurs de l'âge, Grippe humaine (), Humains, Hépatite B (), Pneumonie à pneumocoques (), Tétanos (), Vaccin diphtérie-tétanos-coqueluche (usage thérapeutique), Vaccin diphtérie-tétanos-coqueluche (économie), Vaccination (économie), Vaccins antigrippaux (usage thérapeutique), Vaccins antigrippaux (économie), Vaccins antipneumococciques (usage thérapeutique), Vaccins antipneumococciques (économie), États-Unis d'Amérique.
MESH :
- usage thérapeutique : Vaccin diphtérie-tétanos-coqueluche, Vaccins antigrippaux, Vaccins antipneumococciques.
- économie : Vaccin diphtérie-tétanos-coqueluche, Vaccination, Vaccins antigrippaux, Vaccins antipneumococciques.
- Adulte, Analyse coût-bénéfice, Calendrier vaccinal, Canada, Diphtérie, Facteurs de l'âge, Grippe humaine, Humains, Hépatite B, Pneumonie à pneumocoques, Tétanos, États-Unis d'Amérique.
Wicri :
- geographic : Canada, États-Unis.

English descriptors

KwdEn :
- Adult, Age Factors, Canada, Cost-Benefit Analysis, Diphtheria (prevention & control), Diphtheria-Tetanus-Pertussis Vaccine (economics), Diphtheria-Tetanus-Pertussis Vaccine (therapeutic use), Hepatitis B (prevention & control), Humans, Immunization Schedule, Influenza Vaccines (economics), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Pneumococcal Vaccines (economics), Pneumococcal Vaccines (therapeutic use), Pneumonia, Pneumococcal (prevention & control), Tetanus (prevention & control), United States, Vaccination (economics).
MESH :
- chemical , economics : Diphtheria-Tetanus-Pertussis Vaccine, Influenza Vaccines, Pneumococcal Vaccines.
- chemical , therapeutic use : Diphtheria-Tetanus-Pertussis Vaccine, Influenza Vaccines, Pneumococcal Vaccines.
- geographic : Canada, United States.
- economics : Vaccination.
- prevention & control : Diphtheria, Hepatitis B, Influenza, Human, Pneumonia, Pneumococcal, Tetanus.
- Adult, Age Factors, Cost-Benefit Analysis, Humans, Immunization Schedule.

Abstract

BACKGROUND

Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule.

METHODS

We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios.

RESULTS

The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations.

CONCLUSIONS

The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations.

DOI: 10.1016/j.vaccine.2018.11.056
PubMed: 30527660

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000028
to stream Main, to step Curation: 000028

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of adult vaccinations: A systematic review.</title>
<author><name sortKey="Leidner, Andrew J" sort="Leidner, Andrew J" uniqKey="Leidner A" first="Andrew J" last="Leidner">Andrew J. Leidner</name>
<affiliation wicri:level="1"><nlm:affiliation>Berry Technology Solutions, USA. Electronic address: aleidner@cdc.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Berry Technology Solutions</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Murthy, Neil" sort="Murthy, Neil" uniqKey="Murthy N" first="Neil" last="Murthy">Neil Murthy</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chesson, Harrell W" sort="Chesson, Harrell W" uniqKey="Chesson H" first="Harrell W" last="Chesson">Harrell W. Chesson</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Biggerstaff, Matthew" sort="Biggerstaff, Matthew" uniqKey="Biggerstaff M" first="Matthew" last="Biggerstaff">Matthew Biggerstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoecker, Charles" sort="Stoecker, Charles" uniqKey="Stoecker C" first="Charles" last="Stoecker">Charles Stoecker</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Public Health and Tropical Medicine, Tulane University, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Public Health and Tropical Medicine, Tulane University</wicri:regionArea>
<wicri:noRegion>Tulane University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Harris, Aaron M" sort="Harris, Aaron M" uniqKey="Harris A" first="Aaron M" last="Harris">Aaron M. Harris</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Acosta, Anna" sort="Acosta, Anna" uniqKey="Acosta A" first="Anna" last="Acosta">Anna Acosta</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dooling, Kathleen" sort="Dooling, Kathleen" uniqKey="Dooling K" first="Kathleen" last="Dooling">Kathleen Dooling</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bridges, Carolyn B" sort="Bridges, Carolyn B" uniqKey="Bridges C" first="Carolyn B" last="Bridges">Carolyn B. Bridges</name>
<affiliation wicri:level="1"><nlm:affiliation>Berry Technology Solutions, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Berry Technology Solutions</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30527660</idno>
<idno type="pmid">30527660</idno>
<idno type="doi">10.1016/j.vaccine.2018.11.056</idno>
<idno type="wicri:Area/Main/Corpus">000028</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000028</idno>
<idno type="wicri:Area/Main/Curation">000028</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000028</idno>
<idno type="wicri:Area/Main/Exploration">000028</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of adult vaccinations: A systematic review.</title>
<author><name sortKey="Leidner, Andrew J" sort="Leidner, Andrew J" uniqKey="Leidner A" first="Andrew J" last="Leidner">Andrew J. Leidner</name>
<affiliation wicri:level="1"><nlm:affiliation>Berry Technology Solutions, USA. Electronic address: aleidner@cdc.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Berry Technology Solutions</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Murthy, Neil" sort="Murthy, Neil" uniqKey="Murthy N" first="Neil" last="Murthy">Neil Murthy</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chesson, Harrell W" sort="Chesson, Harrell W" uniqKey="Chesson H" first="Harrell W" last="Chesson">Harrell W. Chesson</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Biggerstaff, Matthew" sort="Biggerstaff, Matthew" uniqKey="Biggerstaff M" first="Matthew" last="Biggerstaff">Matthew Biggerstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoecker, Charles" sort="Stoecker, Charles" uniqKey="Stoecker C" first="Charles" last="Stoecker">Charles Stoecker</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Public Health and Tropical Medicine, Tulane University, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Public Health and Tropical Medicine, Tulane University</wicri:regionArea>
<wicri:noRegion>Tulane University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Harris, Aaron M" sort="Harris, Aaron M" uniqKey="Harris A" first="Aaron M" last="Harris">Aaron M. Harris</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Acosta, Anna" sort="Acosta, Anna" uniqKey="Acosta A" first="Anna" last="Acosta">Anna Acosta</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dooling, Kathleen" sort="Dooling, Kathleen" uniqKey="Dooling K" first="Kathleen" last="Dooling">Kathleen Dooling</name>
<affiliation wicri:level="1"><nlm:affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Center for Immunization and Respiratory Diseases, CDC</wicri:regionArea>
<wicri:noRegion>CDC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bridges, Carolyn B" sort="Bridges, Carolyn B" uniqKey="Bridges C" first="Carolyn B" last="Bridges">Carolyn B. Bridges</name>
<affiliation wicri:level="1"><nlm:affiliation>Berry Technology Solutions, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Berry Technology Solutions</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Canada</term>
<term>Cost-Benefit Analysis</term>
<term>Diphtheria (prevention & control)</term>
<term>Diphtheria-Tetanus-Pertussis Vaccine (economics)</term>
<term>Diphtheria-Tetanus-Pertussis Vaccine (therapeutic use)</term>
<term>Hepatitis B (prevention & control)</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Pneumococcal Vaccines (economics)</term>
<term>Pneumococcal Vaccines (therapeutic use)</term>
<term>Pneumonia, Pneumococcal (prevention & control)</term>
<term>Tetanus (prevention & control)</term>
<term>United States</term>
<term>Vaccination (economics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Analyse coût-bénéfice</term>
<term>Calendrier vaccinal</term>
<term>Canada</term>
<term>Diphtérie ()</term>
<term>Facteurs de l'âge</term>
<term>Grippe humaine ()</term>
<term>Humains</term>
<term>Hépatite B ()</term>
<term>Pneumonie à pneumocoques ()</term>
<term>Tétanos ()</term>
<term>Vaccin diphtérie-tétanos-coqueluche (usage thérapeutique)</term>
<term>Vaccin diphtérie-tétanos-coqueluche (économie)</term>
<term>Vaccination (économie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Vaccins antigrippaux (économie)</term>
<term>Vaccins antipneumococciques (usage thérapeutique)</term>
<term>Vaccins antipneumococciques (économie)</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term>
<term>Influenza Vaccines</term>
<term>Pneumococcal Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term>
<term>Influenza Vaccines</term>
<term>Pneumococcal Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Diphtheria</term>
<term>Hepatitis B</term>
<term>Influenza, Human</term>
<term>Pneumonia, Pneumococcal</term>
<term>Tetanus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccin diphtérie-tétanos-coqueluche</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins antipneumococciques</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccin diphtérie-tétanos-coqueluche</term>
<term>Vaccination</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins antipneumococciques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Immunization Schedule</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Analyse coût-bénéfice</term>
<term>Calendrier vaccinal</term>
<term>Canada</term>
<term>Diphtérie</term>
<term>Facteurs de l'âge</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Hépatite B</term>
<term>Pneumonie à pneumocoques</term>
<term>Tétanos</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
<term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30527660</PMID>
<DateCompleted><Year>2019</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>37</Volume>
<Issue>2</Issue>
<PubDate><Year>2019</Year>
<Month>01</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-effectiveness of adult vaccinations: A systematic review.</ArticleTitle>
<Pagination><MedlinePgn>226-234</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)31581-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.11.056</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule.</AbstractText>
<AbstractText Label="METHODS">We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios.</AbstractText>
<AbstractText Label="RESULTS">The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations.</AbstractText>
<AbstractText Label="CONCLUSIONS">The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations.</AbstractText>
<CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leidner</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo><Affiliation>Berry Technology Solutions, USA. Electronic address: aleidner@cdc.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Murthy</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA; Epidemic Intelligence Service, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chesson</LastName>
<ForeName>Harrell W</ForeName>
<Initials>HW</Initials>
<AffiliationInfo><Affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Biggerstaff</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stoecker</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>School of Public Health and Tropical Medicine, Tulane University, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harris</LastName>
<ForeName>Aaron M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Acosta</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dooling</LastName>
<ForeName>Kathleen</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, CDC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bridges</LastName>
<ForeName>Carolyn B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo><Affiliation>Berry Technology Solutions, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID>
<Agency>Intramural CDC HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>12</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004165" MajorTopicYN="N">Diphtheria</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011018" MajorTopicYN="N">Pneumonia, Pneumococcal</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013742" MajorTopicYN="N">Tetanus</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adults</Keyword>
<Keyword MajorTopicYN="Y">Cost-effectiveness</Keyword>
<Keyword MajorTopicYN="Y">Vaccines</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>08</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>10</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>11</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>12</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>12</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30527660</ArticleId>
<ArticleId IdType="pii">S0264-410X(18)31581-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2018.11.056</ArticleId>
<ArticleId IdType="pmc">PMC6545890</ArticleId>
<ArticleId IdType="mid">NIHMS1023453</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>PLoS One. 2013 Oct 18;8(10):e78548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24205255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2005 Jan;118(1):68-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15639212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2009;27(2):127-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19254046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Dec 5;31(50):6011-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24148572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Mar 3;29(11):2149-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21215340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2010 Dec;10(12):845-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21051295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Care. 2001 Dec;39(12):1273-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11717569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Value Health. 2009 Jul-Aug;12(5):697-707</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19490561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2015 Oct 6;163(7):489-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26344036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Aug 28;371(9):796-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25162885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Sep 03;8(9):e67260</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24019859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1994 Sep 22;331(12):778-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8065407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer. 2007 Jun 1;109(11):2357-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17457827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Jul 30;17 Suppl 1:S67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10471185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29370152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 May 8;24(19):4212-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16546308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2013 Apr;44(4):373-381</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23498103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med Sci. 2007 Dec;334(6):481-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18091370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Prim Prev. 2015 Aug;36(4):259-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26032932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2007 Mar;32(3):186-193</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17296470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Mar 10;26(11):1420-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18272262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Intern Med. 1993 Aug;8(8):405-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8410405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Occup Environ Med. 1997 May;39(5):408-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9172085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 5;30(2):425-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22075091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2012 Feb 22;307(8):804-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22357831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2011 Sep;128(3):e591-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21844056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2018 Feb;54(2):205-213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29246674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Aug 20;31(37):3950-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23806240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2006 Jul;31(1):72-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16777545</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jun 8;34(27):3149-3155</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27161997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2005 Jun;115(6):1675-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15930232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 May 25;35(23):3104-3115</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28457673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2008 May-Jun;4(3):238-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18382137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Apr 4;35(15):1828-1843</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28284681</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Serv Res. 1993 Apr;28(1):97-121</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8463111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2009;27(12):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19908924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Dec 15;49(12):1784-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19911967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Rep. 2015 Dec;26(12):16-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26676235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S128-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21640230</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2008 Aug;7(6):753-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18665775</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Jan;13(1):28-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17370513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2016 Jun 15;183(12):1159-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27188951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2008 Jul;35(1):25-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18541174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 Dec 13;21(3-4):312-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12450707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2000 Oct 4;284(13):1655-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11015795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1986 Jan;104(1):79-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3079638</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2016 Sep 13;316(10):1093-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27623463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 May 15;20 Suppl 2:S21-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12110251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2004;22(11):719-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15250750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2018 Feb 09;67(5):156-157</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29420458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2012 Jan 1;72(1):35-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22191794</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(7):e22308</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21829456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2006 Jun;30(6):498-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16704944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Obstet Gynecol. 2012 Feb;119(2 Pt 1):306-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22270282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2012 Mar 26;72(5):715-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22413761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Nov 27;33 Suppl 4:D114-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26615170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Gastroenterol. 2013 Jan;108(1):120-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23247579</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Nov;10(11):1915-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15550200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1994 Dec 15;121(12):947-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7978721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2015 Dec;15(12):1459-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26362172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Aug 21;359(8):821-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18716299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2018 Feb 1;14(2):430-441</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29194019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2002 Aug 20;137(4):225-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12186512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2006 Sep 5;145(5):317-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16954357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 Jan 31;20(9-10):1383-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11818157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can J Public Health. 2000 Sep-Oct;91(5):334-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11089284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Aug 6;32(36):4602-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24996123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2000 Jan;30(1):157-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10619745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1980 Sep 4;303(10):553-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6772950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Dec 19;35(52):7292-7296</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29132991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27387669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2014 Feb 4;160(3):161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24658693</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can J Public Health. 2011 Nov-Dec;102(6):445-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22164556</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Aug 6;27(36):4891-904</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19520205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1993 Feb 15;118(4):298-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8420448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2007 May 15;44(10):1280-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17443464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Mar 25;31(13):1680-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22659447</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Emerg Med. 1999 Mar;33(3):299-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10036344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2008;26(3):191-215</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18282015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2018 Feb 1;36(6):890-898</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29329685</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Nov 27;33 Suppl 4:D83-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26615174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Jan 23;32(5):618-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24291539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1982 Sep 9;307(11):644-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6810170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Infect Control. 2016 Sep 1;44(9):1004-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27372226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Obstet Gynecol. 2006 Jun;107(6):1323-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16738159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2014 Sep 26;63(38):839-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25254561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2001 Mar 12;161(5):749-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11231710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009 Jul 16;4(7):e6284</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19606227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Surveill Summ. 2017 May 05;66(11):1-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28472027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Prev Med. 2001 Jul;21(1):29-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11418254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Manag Care. 2010 Mar;16(3):200-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20225915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2013 Jan;36(1):63-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22933435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 May 1;21(16):1769-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12686092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2016 Aug;34(8):723-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26914091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20528406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 May 21;27(24):3159-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19446186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2017 Feb 7;166(3):209-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28166560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Public Health Rep. 2016 Mar-Apr;131(2):320-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26957667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S45-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12369231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Nov 28;25(49):8326-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17980938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Intern Med. 2017 Feb;32(2):159-167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27743284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2003 Jun 17;138(12):960-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12809452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jul 20;25(29):5399-408</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17561316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2009 Oct 20;151(8):538-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19841455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2016 Sep;34(9):847-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27178048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Fam Med. 2017 Jan;15(1):23-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28376458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2015 Jul 17;64(27):746-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26182193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2013 Feb;31(2):125-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23335045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2003;21(1):13-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12484801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2008;26(2):163-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18198935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Emerg Med. 2012 Sep;30(7):1072-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21908140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2018 Feb 14;36(8):1093-1100</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29366706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28837546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Mar 26;32(15):1645-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24534737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Apr 4;34(15):1832-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26899377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Nov 10;28(48):7620-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20887828</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2017 Nov 2;13(11):2646-2653</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29028414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Jan 09;9(1):e72723</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24416118</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1997 Oct 22-29;278(16):1333-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9343464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Dec 5;32(51):6941-6947</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25444820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Public Health Rep. 2008 Jul-Aug;123(4):504-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18763413</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Leidner, Andrew J" sort="Leidner, Andrew J" uniqKey="Leidner A" first="Andrew J" last="Leidner">Andrew J. Leidner</name>
</noRegion>
<name sortKey="Acosta, Anna" sort="Acosta, Anna" uniqKey="Acosta A" first="Anna" last="Acosta">Anna Acosta</name>
<name sortKey="Biggerstaff, Matthew" sort="Biggerstaff, Matthew" uniqKey="Biggerstaff M" first="Matthew" last="Biggerstaff">Matthew Biggerstaff</name>
<name sortKey="Bridges, Carolyn B" sort="Bridges, Carolyn B" uniqKey="Bridges C" first="Carolyn B" last="Bridges">Carolyn B. Bridges</name>
<name sortKey="Chesson, Harrell W" sort="Chesson, Harrell W" uniqKey="Chesson H" first="Harrell W" last="Chesson">Harrell W. Chesson</name>
<name sortKey="Dooling, Kathleen" sort="Dooling, Kathleen" uniqKey="Dooling K" first="Kathleen" last="Dooling">Kathleen Dooling</name>
<name sortKey="Harris, Aaron M" sort="Harris, Aaron M" uniqKey="Harris A" first="Aaron M" last="Harris">Aaron M. Harris</name>
<name sortKey="Murthy, Neil" sort="Murthy, Neil" uniqKey="Murthy N" first="Neil" last="Murthy">Neil Murthy</name>
<name sortKey="Stoecker, Charles" sort="Stoecker, Charles" uniqKey="Stoecker C" first="Charles" last="Stoecker">Charles Stoecker</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000027 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000027 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30527660
   |texte=   Cost-effectiveness of adult vaccinations: A systematic review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30527660" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Cost-effectiveness of adult vaccinations: A systematic review.

Cost-effectiveness of adult vaccinations: A systematic review.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki